Awiqli® (insulin icodec) injection, if approved, has the potential to be the first once-weekly basal insulin treatment available in the US for adult type 2 diabetes In adults with type 2 diabetes ...
New half-year of business growth (+3%) in the 1st half of 2025, in a demanding international environment Strong EBITDA growth of +82% - EBITDA margin of 7.2% (vs. 4.1%) +€1.2 million improvement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback